Treatment of glioblastoma in elderly patients: An overview of current treatments and future perspective

Gaetano Lanzetta, Giuseppe Minniti

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Current treatment of glioblastoma in the elderly includes surgery, radiotherapy and chemotherapy, but the prognosis remains extremely poor, and its optimal management is still debated. Longer survival after extensive resection compared with biopsy only has been reported, although the survival advantage remains modest. Radiation in the form of standard (60 Gy in 30 fractions over 6 weeks) and abbreviated courses of radiotherapy (30-50 Gy in 6-20 fractions over 2-4 weeks) has been employed in elderly patients with glioblastoma, showing survival benefits compared with supportive care alone. Temozolomide is an alkylating agent recently employed in older patients with newly diagnosed glioblastoma. The addition of concomitant and/or adjuvant chemotherapy with temozolomide to radiotherapy, which is currently the standard treatment in adults with glioblastoma, is emerging as an effective therapeutic option for older patients with favorable prognostic factors. The potential benefits on survival, improvement in quality of life and toxicity of different schedules of radiotherapy plus temozolomide need to be addressed in future randomized studies.

Original languageEnglish
Pages (from-to)650-658
Number of pages9
JournalTumori
Volume96
Issue number5
Publication statusPublished - Sep 2010

Fingerprint

temozolomide
Glioblastoma
Radiotherapy
Survival
Alkylating Agents
Therapeutics
Adjuvant Chemotherapy
Appointments and Schedules
Quality of Life
Radiation
Biopsy
Drug Therapy

Keywords

  • Chemotherapy
  • Elderly
  • Glioblastoma
  • Radiotherapy
  • Surgery
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of glioblastoma in elderly patients : An overview of current treatments and future perspective. / Lanzetta, Gaetano; Minniti, Giuseppe.

In: Tumori, Vol. 96, No. 5, 09.2010, p. 650-658.

Research output: Contribution to journalArticle

Lanzetta, Gaetano ; Minniti, Giuseppe. / Treatment of glioblastoma in elderly patients : An overview of current treatments and future perspective. In: Tumori. 2010 ; Vol. 96, No. 5. pp. 650-658.
@article{e6da090e9e774c3d898082fc08204070,
title = "Treatment of glioblastoma in elderly patients: An overview of current treatments and future perspective",
abstract = "Current treatment of glioblastoma in the elderly includes surgery, radiotherapy and chemotherapy, but the prognosis remains extremely poor, and its optimal management is still debated. Longer survival after extensive resection compared with biopsy only has been reported, although the survival advantage remains modest. Radiation in the form of standard (60 Gy in 30 fractions over 6 weeks) and abbreviated courses of radiotherapy (30-50 Gy in 6-20 fractions over 2-4 weeks) has been employed in elderly patients with glioblastoma, showing survival benefits compared with supportive care alone. Temozolomide is an alkylating agent recently employed in older patients with newly diagnosed glioblastoma. The addition of concomitant and/or adjuvant chemotherapy with temozolomide to radiotherapy, which is currently the standard treatment in adults with glioblastoma, is emerging as an effective therapeutic option for older patients with favorable prognostic factors. The potential benefits on survival, improvement in quality of life and toxicity of different schedules of radiotherapy plus temozolomide need to be addressed in future randomized studies.",
keywords = "Chemotherapy, Elderly, Glioblastoma, Radiotherapy, Surgery, Temozolomide",
author = "Gaetano Lanzetta and Giuseppe Minniti",
year = "2010",
month = "9",
language = "English",
volume = "96",
pages = "650--658",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Treatment of glioblastoma in elderly patients

T2 - An overview of current treatments and future perspective

AU - Lanzetta, Gaetano

AU - Minniti, Giuseppe

PY - 2010/9

Y1 - 2010/9

N2 - Current treatment of glioblastoma in the elderly includes surgery, radiotherapy and chemotherapy, but the prognosis remains extremely poor, and its optimal management is still debated. Longer survival after extensive resection compared with biopsy only has been reported, although the survival advantage remains modest. Radiation in the form of standard (60 Gy in 30 fractions over 6 weeks) and abbreviated courses of radiotherapy (30-50 Gy in 6-20 fractions over 2-4 weeks) has been employed in elderly patients with glioblastoma, showing survival benefits compared with supportive care alone. Temozolomide is an alkylating agent recently employed in older patients with newly diagnosed glioblastoma. The addition of concomitant and/or adjuvant chemotherapy with temozolomide to radiotherapy, which is currently the standard treatment in adults with glioblastoma, is emerging as an effective therapeutic option for older patients with favorable prognostic factors. The potential benefits on survival, improvement in quality of life and toxicity of different schedules of radiotherapy plus temozolomide need to be addressed in future randomized studies.

AB - Current treatment of glioblastoma in the elderly includes surgery, radiotherapy and chemotherapy, but the prognosis remains extremely poor, and its optimal management is still debated. Longer survival after extensive resection compared with biopsy only has been reported, although the survival advantage remains modest. Radiation in the form of standard (60 Gy in 30 fractions over 6 weeks) and abbreviated courses of radiotherapy (30-50 Gy in 6-20 fractions over 2-4 weeks) has been employed in elderly patients with glioblastoma, showing survival benefits compared with supportive care alone. Temozolomide is an alkylating agent recently employed in older patients with newly diagnosed glioblastoma. The addition of concomitant and/or adjuvant chemotherapy with temozolomide to radiotherapy, which is currently the standard treatment in adults with glioblastoma, is emerging as an effective therapeutic option for older patients with favorable prognostic factors. The potential benefits on survival, improvement in quality of life and toxicity of different schedules of radiotherapy plus temozolomide need to be addressed in future randomized studies.

KW - Chemotherapy

KW - Elderly

KW - Glioblastoma

KW - Radiotherapy

KW - Surgery

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=78650429307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650429307&partnerID=8YFLogxK

M3 - Article

C2 - 21302607

AN - SCOPUS:78650429307

VL - 96

SP - 650

EP - 658

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -